Top Players and Market Competition in the Asthma and Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry

The market for asthma and chronic obstructive pulmonary disease (COPD) medications is set to experience substantial growth in the coming years. Advancements in drug development, demographic changes, and evolving treatment approaches are all contributing to a promising outlook. Below, we delve into the market size projections, key drivers, leading players, notable trends, and the main segments shaping this industry.

Projected Market Size and Growth Trajectory for Asthma and COPD Drugs
The asthma and COPD drugs market is anticipated to expand significantly, reaching a value of $55.67 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 9.3% during the forecast period. Factors fueling this increase include breakthroughs in biologic drug innovation, an aging global population, worsening air quality, personalized respiratory treatments, and the rising use of homecare respiratory solutions. Important trends predicted for this period involve the broader use of combination inhaler therapies, greater adoption of long-acting bronchodilators, the expansion of biologic treatments especially for severe asthma, a shift toward managing respiratory conditions at home, and growing demand for generic inhalation medications.

Download a free sample of the asthma and chronic obstructive pulmonary disease (copd) drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Factors Propelling Market Expansion in Asthma and COPD Drugs
One of the central forces behind the expanding asthma and COPD drugs market is ongoing innovation in biologic therapies. These advanced drugs offer more targeted and effective treatment options, particularly for patients with severe or difficult-to-treat respiratory conditions.
Additionally, demographic shifts such as the increasing number of elderly individuals worldwide are driving demand. Older populations tend to have higher incidences of respiratory illnesses, which boosts the need for improved medications. Environmental concerns like worsening air pollution also exacerbate respiratory diseases, further widening the market scope.

Top Pharmaceutical Companies Leading the Asthma and COPD Drugs Sector
The competitive landscape of the asthma and COPD drugs market features several prominent pharmaceutical firms, including:
Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, and Takeda Pharmaceutical Company Ltd.
In a notable development in February 2024, UK-based GSK plc acquired Aiolos Bio for an undisclosed sum. This strategic move aims to strengthen GSK's portfolio of asthma and respiratory biologics by adding Aiolos Bio's investigational therapy AIO-001, a long-acting anti-TSLP monoclonal antibody intended for adults with severe asthma, including those exhibiting low T2 inflammation. Aiolos Bio is a US biotechnology firm focused on pioneering treatments for unmet respiratory needs.

View the full asthma and chronic obstructive pulmonary disease (copd) drugs market report:
https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Shaping the Asthma and COPD Drugs Market
Pharmaceutical companies are increasingly focusing on innovative drug combinations to improve treatment outcomes. One prominent trend is the development of rescue inhalers combining short-acting beta-agonists (SABA) with inhaled corticosteroids (ICS). These dual-action inhalers provide rapid relief of symptoms while simultaneously addressing inflammation, thus offering enhanced disease control and reducing the risk of severe asthma attacks.
For example, in January 2024, AstraZeneca introduced AIRSUPRA (albuterol/budesonide) in the US market. This fixed-dose SABA-ICS rescue inhaler uses the company's pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA is designed to quickly alleviate asthma symptoms and prevent sudden severe breathing difficulties by delivering both bronchodilator and anti-inflammatory effects together.

Asthma and COPD Drugs Market Segmentation Overview
The market is categorized into several key segments to better analyze demand and product use:
1) Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
2) Route of Administration: Inhalation, Oral, Injection, Other Methods
3) Patient Group: Adult, Pediatric, Geriatric
4) Application: Asthma, Chronic Obstructive Pulmonary Disease
5) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Further subdivisions include:
- Bronchodilators such as Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, and Methylxanthines
- Corticosteroids including Inhaled, Oral, and Intravenous forms
- Combination Drugs like LABA + ICS, LABA + LAMA, and triple combinations of LABA + LAMA + ICS
- Leukotriene Modifiers encompassing Leukotriene Receptor Antagonists and Leukotriene Synthesis Inhibitors

This segmentation provides a comprehensive framework to understand the diverse range of therapies and delivery methods catering to different patient needs within the asthma and COPD treatment landscape.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.